Skip to main content
OpenTrials
Completed

NCT Number: NCT00348543

Prophylactic Laser Treatment of Drusen Maculopathy

To study the effect of mild laser treatment on the incidence of exudative complications in soft drusen maculopathy. We hypothesise that mild laser treatment causing a proliferation of the retinal pigment epithelium and enhancing the capacity of clearing drusen material from Bruch's membrane.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age-Related Macular Degeneration Eye Diseases Macular Degeneration Retinal Degeneration Retinal Diseases

Age range

55 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Dept of Ophthalmology, Linköping University

Linköping, SE-581 85, Sweden

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • > 55 years of age,
  • Soft drusen maculopathy,
  • VA 0.8-1.0

Exclusion criteria

  • VA <0.8,
  • Pigment clumps,
  • PED,
  • CNV,
  • Atrophy,
  • Haemorrhage,
  • Diabetes retinopathy,
  • Sign cataract,
  • Glaucoma

Treatment and study plan

Laser treatment

Procedure

Primary outcomes

  1. Change in visual acuity

Secondary outcomes

  1. incidence of exudative complications

Sponsors and collaborators

Lead sponsor

University Hospital, Linkoeping

Other

Registry information

Official study title

Prophylactic Laser Treatment of Drusen Maculopathy in Age-related Macular Degeneration.

Important dates

Study start
1999
Study completion
2006
First posted
Jul 4, 2006
Registry last updated
Aug 5, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.